Here we can see the anti-CD20 FAB light (yellow) and heavy (grey) chains bound to the CD20 Receptor (blue) lodged in a membrane. This is the natural orientation of CD20 and the FAB found in protein dataset 20SL. On top of the FAB complex is the ETB scaffolding. The Shiga-like Toxin is composed of two protein chains, A1 and A2. A1 (red) is the larger protein and is responsible for inactivating ribosomes. A2 (dark magenta) is the smaller protein. Grafted onto the Shiga-like Toxin is the Cytomegalovirus
This is a 3D print of Apaf-1 activating Caspase-9, a key protein involved in apoptosis, or programmed cell death. This model is colored by individual protein chains, with Caspace-9 colored shades of blue and Apaf-1 colored shades of magenta.
MT-3724 is a new to immunotherapy from Molecular Templates, currently under investigation for the treatment of non-Hodgkin’s Lymphoma. This immunotoxin is based on Molecular Templates’ Engineered Toxic Bodies (ETBs) drug delivery platform and harnesses the immunotherapy power of receptor-specific targeting. MT-3724 demonstrates a unique mechanism of action, packing a cytotoxic 1-2-3 cancer killing punch.
This is a 3D print of X-ray crystallography dataset 4HJO, the Crystal Structure of the Inactive EGFR Tyrosine Kinase Domain with Erlotinib. 4TRP
Epidermal growth factor receptor (EGFR) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα) (note, a full list of the ligands able to activate EGFR and other members of the ErbB family is given in the ErbB article). ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as EGFR. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer.
Inactive EGFR Tyrosine Kinase 3D Molecular Visualization
This 3D animation depicts EGFR bound by Erlotinib. Important protein structures like the alphaC-Helix, P-Loop and A-Loop are visualized to identify EGFR’s active state.
“Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signaling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.”
Inactive EGFR 3D Visualization
[caption id="attachment_2268" align="alignnone" width="645"] Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain[/caption]
If you’d like to explore EGFR, you can purchase a 3D print of EGFR in both its active and inactive state. Models available in multiple sizes and materials.
Let us know if you’d like to request a customization or have a need for a protein model.
Shipping and discount codes are added at checkout.